Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Each of the chapters in Disinfection of Viruses touches on virucidal efficacy for SARS-CoV-2, the causative agent for the COVID-19 disease, or enveloped viral surrogates. SARS-CoV-2 is an enveloped virus of the Coronaviridae family and therefore is expected to be susceptible to all classes of microbicides. The book is divided into three sections. Section 1: "Microbicides for Viral Inactivation," includes chapters on the efficacy of chemical virucides, Section 2: "Physical Inactivation Approaches," includes a chapter on the efficacy of gamma irradiation, ultraviolet light, and heat for inactivating coronaviruses, and Section 3: "Viral Persistence and Disinfection," includes data on viral persistence for SARS-CoV-2, as these data inform the need for and the approaches that might be used for disinfection.

Antiviral agents. --- Herbs --- Therapeutic use.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral agents. --- Antiviral drugs --- Antivirals --- Anti-infective agents --- Virus diseases --- Virus inhibitors --- Chemotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Medical microbiology, virology, parasitology --- General virology --- Virology --- Viruses --- Virus diseases --- Virologie --- Virus --- Maladies à virus --- Periodicals --- Périodiques --- Virology. --- human viruses --- plant viruses --- antiviral agents --- vaccines --- animal viruses --- infection control --- Microbiology --- Infectious Disease Medicine --- Infectious diseases. Communicable diseases --- besmettelijke ziekten --- Microbiology & Immunology --- Virologie.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This is a detailed manual giving a step by step approach to undertaking the pharmacovigilance of antiretrovirals. it is intended to be a source of practical advice for Pharmacovigilance Centres and health professionals involved in HIV/AIDS prevention and treatment programmes. There is an urgent need to develop robust pharmacovigilance systems for antiretrovirals particularly in resource-limited settings. This detailed manual gives a step by step approach to undertaking the pharmacovigilance of these medicines. Good pharmacovigilance will identify the risks in the shortest possible time after t

Antiretroviral agents. --- Drug Monitoring. --- Drug monitoring -- Handbooks, manuals, etc. --- Drug Utilization Review -- methods. --- Antiretroviral agents --- Drug monitoring --- Drug Utilization Review --- Adverse Drug Reaction Reporting Systems --- Methods --- Drug Monitoring --- Handbooks --- Anti-Retroviral Agents --- Drug Information Services --- Drug Utilization --- Publication Formats --- Antiviral Agents --- Utilization Review --- Monitoring, Physiologic --- Investigative Techniques --- Product Surveillance, Postmarketing --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Evaluation Studies as Topic --- Pharmaceutical Services --- Information Services --- Publication Characteristics --- Anti-Infective Agents --- Pharmacy Administration --- Diagnostic Techniques and Procedures --- Quality Assurance, Health Care --- Quality of Health Care --- Health Services --- Organization and Administration --- Diagnosis --- Health Services Administration --- Therapeutic Uses --- Information Science --- Health Care Quality, Access, and Evaluation --- Health Care --- Pharmacologic Actions --- Health Care Facilities, Manpower, and Services --- Chemical Actions and Uses --- Chemicals and Drugs --- Clinical Immunology --- Medicine --- Health & Biological Sciences --- Drugs --- Monitoring, Drug --- Therapeutic drug monitoring --- Anti-retroviral agents --- Antiretroviral drugs --- Antiretrovirals --- Monitoring --- Patient monitoring --- Antiviral agents --- Analysis --- Testing

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.

Zika virus --- nucleoside analogues --- antiviral agents --- NS5 --- prodrugs --- ProTides --- neural stem cells --- RNA-dependent RNA polymerase --- cytomegalovirus --- latent infection --- TALEN --- Surveyor nuclease mutation detection assay --- ie-1 gene --- quantitative real-time PCR --- Epstein–Barr virus --- herpes viruses --- lytic gene expression --- Burkitt lymphoma cells --- clozapine --- antipsychotic drug --- antiviral drug --- enteroviruses --- coxsackievirus B4 --- persistent infection --- fluoxetine --- resistance --- mutations --- herpes B virus --- macacine herpesvirus-1 --- genistein --- flavonoids --- acyclovir --- ganciclovir --- Plantago asiatica --- Clerodendrum trichotomum --- RSV --- therapeutic effects --- acteoside --- human antimicrobial peptides --- antiviral strategies --- defensins --- cathelicidins --- hepcidins --- transferrins --- influenza A virus --- brevilin A --- antiviral --- sesquiterpene lactone --- replication --- PRRSV --- polyethylenimine --- PEI --- virion internalization --- endocytosis --- HIV --- pediatrics --- Ethiopia --- pre-treatment drug resistance --- combination antiretroviral therapy (cART) --- dried plasma spots --- dried blood spots --- sphingolipids --- glycosphingolipids --- viruses --- lipid biosynthesis --- flavivirus --- Japanese encephalitis virus --- furin inhibitor --- precursor membrane protein --- measles virus --- central nervous system --- tropism --- treatments --- porcine reproductive and respiratory syndrome virus --- ginsenoside Rg1 --- antiviral activity --- pro-inflammatory factor --- NF-κB signaling pathway --- acute/latent infection --- congenital infection --- antiviral agent --- therapeutic strategies --- nucleic acid-based therapeutic approach --- HCMV vaccine --- adoptive cell therapy --- Rev response element --- chemical footprinting --- SHAPE --- drug discovery --- branched peptides --- herpesvirus --- immediate-early --- IE1 --- IE2 --- ribozyme --- RNA interference --- CRISPR/Cas --- small molecule --- orthohantavirus --- phenyl-benzotriazoles --- C-FRA --- Porcine circovirus type 2 --- epigallocatechin gallate --- heparan sulfate --- antiviral effect --- virus attachment --- microvirin --- lectin --- human immunodeficiency virus --- hepatitis C virus --- antiviral inhibitor --- non-immunogenic --- viral entry --- protein drugs --- LUMS1 --- oleanane-type derivatives --- influenza A virus (IAV) --- virus entry inhibitors --- hemagglutinin (HA) --- n/a --- Epstein-Barr virus